CHMP Backs CORT's Lifyorli Combo: Time to Buy?
💡 Key Takeaway
CHMP's positive opinion for Lifyorli in platinum-resistant ovarian cancer is a major regulatory win for CORT, potentially accelerating EU approval and boosting its commercial outlook.
CHMP Endorses Lifyorli Combination for Platinum-Resistant Ovarian Cancer
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has issued a positive opinion for Lifyorli (relacorilant) in combination with nab-paclitaxel for the treatment of platinum-resistant ovarian cancer. This opinion is a critical step toward marketing authorization in the European Union, which is typically granted within 67 days of a positive CHMP opinion.
Lifyorli is a selective glucocorticoid receptor modulator developed by Corcept Therapeutics (CORT). The combination therapy aims to improve outcomes for patients with platinum-resistant ovarian cancer, a difficult-to-treat condition with limited options.
The positive opinion is based on results from a Phase 3 study that demonstrated a statistically significant improvement in progression-free survival and overall survival compared to chemotherapy alone. This is the first regulatory endorsement for Lifyorli in this indication.
Corcept has already launched Lifyorli in the U.S. for Cushing's syndrome, generating $47.6 million in its first commercial quarter (Q2 2026). The company is also pursuing additional indications, including a December 2026 FDA target action date for Cushing's syndrome.
The CHMP opinion does not guarantee approval, but it is a strong signal that European regulators view the therapy favorably. A final decision from the European Commission is expected in the coming months.
Why This Regulatory Milestone Is a Game-Changer for CORT
A positive CHMP opinion significantly de-risks the European approval pathway for Lifyorli. It validates the drug's efficacy and safety profile, making a future EU launch highly likely. This opens up a new market for Corcept, which currently generates revenue primarily from its Cushing's syndrome franchise.
Platinum-resistant ovarian cancer represents a substantial unmet medical need, with a global market estimated at over $2 billion annually. If approved, Lifyorli could capture a meaningful share, especially as the first glucocorticoid receptor modulator approved for this indication.
The news also strengthens Corcept's pipeline story. Success in oncology could pave the way for further expansion into other solid tumors, enhancing long-term growth prospects. Investors have been closely watching Corcept's transition from a one-drug company to a diversified biopharma, and this milestone supports that narrative.
From a financial perspective, the European approval could add hundreds of millions in peak sales, though the exact timing and pricing remain uncertain. The company's strong Q2 2026 revenue from Cushing's syndrome provides a solid commercial foundation, reducing the risk associated with the launch.
Overall, this is a positive catalyst that could drive analyst upgrades and increased institutional interest. However, competition from other therapies and the need for successful reimbursement negotiations in Europe are key risks to monitor.
Source: Zacks Investment Research
Analysis generated by Bobby AI quantitative model, reviewed and edited by our research team. This is not financial advice. Always do your own research before making investment decisions.
Bobby Insight
Buy CORT on this regulatory catalyst, as it opens a new oncology market and reinforces the company's growth trajectory.
The CHMP opinion is a major de-risking event that could lead to EU approval and launch, adding a new revenue stream. With strong initial sales in Cushing's syndrome and a deep pipeline, CORT is well-positioned for long-term growth. The stock may see near-term volatility, but the risk-reward is favorable for patient investors.
What This Means for Me
